Cuorips (4894) · RiskReframed
Dependence on research results and licenses from Osaka University, Kyoto University and others
First written in FY2023. 1 of 2 entries say "Reframed", first in FY2026. Latest entry: FY2026.
2entries
4years
0from disclosures
How it moved
Same theme, other companies
Risk of dependence on joint R&D counterparties and termination of agreementsA theme 16 companies write about · 19 as a headwind · 0 as a tailwind
Cuorips moved to the "Worse" side of this theme in 2026, 3 years after the typical company in this theme (2023).
The whole theme swung hardest in 2020: 2 of 6 companies on the "Worse" side.
3 other companies' latest entry also says "Reframed".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 16 companies compared. The sentences above are computed from all 16.Full recordFilings, disclosures and news, newest first
- FY2026ReframedAnnual report
「Although the joint research chair ended in September 2025, we continue to conduct various joint research projects with Osaka University, which remains an important partner in the Group’s research and development activities.」
The leading-edge regenerative medicine joint research chair at Osaka University ended, but joint research and relationships involving patents and know-how continue, changing the form of the dependence. - FY2023First statedAnnual report
「Osaka University remains an important partner in our research and development activities.」
The company discloses dependence on Osaka University’s research results, joint research chairs, patents and clinical-trial results, as well as on iPS cells and patent licenses originating from Kyoto University. Refusal to renew, termination or unfavorable amendments to agreements are cited as risks of delaying research and development.